Barbara McGowan

May 30, 2024 | radcliffecardiology.com | Harriette Van Spall |Harold Bays |Sven Francque |Barbara McGowan

ECO 2024 — Dr Donna H Ryan (Pennington Biomedical Research Center, US) joins us to discuss the first sub-analysis of the landmark SELECT trial (NCT03574597, Novo Nordisk). In this study, investigators looked at long-term weight loss with semaglutide 2.4 mg compared to a placebo among 17,604 participants. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss compared to placebo. Weight loss was sustained over 4 years.

May 29, 2024 | radcliffecardiology.com | Harold Bays |Sven Francque |Barbara McGowan |Donna Ryan

Video Published: Views: 31 Likes: 0 Average (ratings) ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA. Questions1. What is the background of this combinatory approach? 2. What data did you present at ERA 24? 3. What are the challenges and opportunities in approaching combinatory treatment? 4.

Mar 29, 2024 | onlinelibrary.wiley.com | Rachel Gibson |Nick Oliver |Barbara McGowan |Nicola Guess

There is a need to reduce the barriers to healthy eating reported by shift workers living with type 2 diabetes working in the healthcare setting. The findings from this intervention development consultation workshop with key stakeholders support the need for multi-level interventions.

Oct 17, 2023 | newstatesman.com | Barbara McGowan

BMI remains an important measurement system, particularly at the population level when assessing health with regards to body mass. To calculate BMI, only a height and weight measurement are needed, which means that it is an inexpensive, accessible, and easy-to-measure metric. These factors are important when trying to assess lots of people in a population, either when screening or assessing risk.